Thursday, July 31, 2014

Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline’s HPV vaccine

[

| E-mail

]


Contact: Andrew Thompsonandrew@landesbioscience.comLandes Bioscience


A long-term follow-up study (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity and safety of GlaxoSmithKline’s human papilloma virus (HPV) vaccine Cervarix. Women vaccinated with…

Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline’s HPV vaccine




No comments:

Post a Comment